The animal health sector is adapting to a rapidly changing and increasingly complex environment: new pathologies, growing regulatory requirements, technological complexity, and pressure on time-to-market.

Faced with these challenges, the goal is no longer limited to individual internal capabilities: it is now about selecting the best scientific expertise and combining it with the specific expertise of the CDMO and its client.

To offer solutions that quickly meet market expectations, success relies on creating targeted synergies and expanded strategic partnerships.

It is in this context that AB7 is introducing a new CXDMO approach.

Why the CXDMO model?

A CDMO traditionally supports its clients in the development, formulation, industrialisation, and manufacturing of a specific product.

The CXDMO goes further : it connects AB7’s internal expertise with that of technology and commercial partners to build innovative, bespoke, and market-ready solutions.

The "X" adds three new dimensions to the classic CDMO offering:

eXtended — Expanding the ecosystem
Leveraging expert partners and complementary skills to enhance R&D capabilities and unlock new technical solutions.

Cross-innovation — Connecting expertise
Combining external innovations with AB7’s know-how to transform technologies into concrete, compliant, and scalable solutions.

eXpectation — Meeting needs
Building bespoke solutions tailored to the specific challenges of each project and market expectations.

The three pillars of the CXDMO model

The CXDMO is based on the synergy between three key players:

1. Technology partners

Academic partners, biotechs, start-ups, and industrial specialists provide cutting-edge technologies and high-value innovations that have already been validated at the experimental stage (proof of concept), supported by preliminary efficacy and safety data.

2. AB7

AB7 acts as the orchestrator, bridging the gap between breakthrough technology and the market. We select innovations with genuine potential for animal health that align perfectly with our expertise and scope. We then leverage our know-how in galenics, regulation, and industrialisation to transform these technologies into compliant, production-ready solutions.

3. Distributors and commercial partners

Veterinary laboratories and distribution players provide their market knowledge, therapeutic expertise, commercial acumen, and mastery of distribution networks. Their collaboration with AB7 enables the development and commercialisation of innovative, differentiating veterinary solutions, while optimising project management and accelerating time-to-market.

The benefits for partners

For technology partners

Broadening the range of applications and securing a route to market.

AB7 provides the R&D expertise tailored to animal health, galenic mastery, and the industrial know-how required to transform a promising innovation into a market-ready solution.

‍

For commercial partners

Accessing differentiating, turnkey solutions

AB7 orchestrates the entire validation and decision-making chain, from selecting promising technologies to their industrialisation, to provide distributors and laboratories with turnkey solutions tailored to market needs.

‍

For all stakeholders

Greater complementarity. More agility. More possibilities.

By connecting the best expertise around a single project, the CXDMO facilitates communication, accelerates development and allows for industrial and regulatory constraints to be anticipated from the very first stages.

‍

A new way to drive innovation forward

With the CXDMO, AB7 is evolving its role from developer and manufacturer to orchestrator of collaborative innovation in animal health.

Are you looking to leverage a new technology or work with us on bringing innovative veterinary solutions to market?
Contact our teams to orchestrate your project.

AB7 CXDMO – eXtended. X-innovation. eXpectation.